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Summary The precise mechanism of fever and flu-like syndrome that occurs in treatment with deoxycytidine analogues remains unclear. This
study demonstrated a strong correlation between plasma interleukin 6 levels and fever in treatment with oral (E)-2'-deoxy-2'(fluoro-
methylene)cytidine. another deoxycytidine analogue.
Keywords: flu-like symptoms; interleukin 6; deoxycytidine analogue
Gemcitabine. a nucleoside analogue. is a potent inhibitor of
ribonucleoside diphosphate reductase. a key enzyme involved in
DNA svnthesis and therefore a target for cancer chemotherapy.
Gemcitabine has shown significant anti-tumour activitv arainst
several malignancies. and induces neutropenia and flu-like symp-
toms (Abbruzzese et al. 1991: Poplin et al. 1992: Abratt et al.
1994: O Rourke et al. 1994: Anderson et al. 1994. 1996) Howvever.
the precise mechanism offever and flu-like svndrome in treatment
,with gemcitabine remains unclear.
(E)-2'-deoxN--2-(fluoromethvlene cy-tidine (FMdC) synthesized
at the Hoechst Marion Roussel Research Institute (Cincinnati. OH.
USA) is another new deoxycytidine analogue. As flu-like symp-
toms were highly suggestive ofcytokine release by deoxycytidine
analogues. this study was performed to inxestigate cvtokine blood
levels in relation to flu-hke symptoms in a phase I trial of oral
FMdC administered dailv for 5 consecutive davs.
MATERIALS AND METHODS
Ten patients with non-small-cell lung cancer wvere treated wvith
FMdC at doses from 2 to 8 mg m- day-' for 5 days. Heparinized
blood samples (3 ml) for the cytokine study v-ere obtained before
treatment and at 8 and 24 h after oral administration on days 1 and
5. The blood was centrifuged immediately. and the plasma thus
obtained was stored at -20 C until analysis. Cvtokine levels were
assayed bv enzyme-linked immunosorbent assay (ELISA) using
commercially available kits [interleukin 2 (IL-)). Genzxme.
Boston. MA USA: interleukin 6 (IL-6). R & D svstem.
Minneapolis. MN USA: tumour necrosis factor (TNF). T-Cell
Science. Cambridge. MA. USA]. The limits of detection were
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O. pg ml-'. 0.094 pgml-' and50 pg ml-' for IL-2. IL-6 andTNF
respectively.
RESULTS
Seven patients suffered from flu-like symptoms with high fever
and aeneral malaise. The effect of dailN FMdC administration on
IL-6 induction in ten patients is demonstrated in Figure 1. The
most striking, findina in this studv w-as that eight of ten patients
dexeloped a significant rise in plasma lexels of IL-6 after repeated
doses. Before treatment. median 11-6 levels were 6.36 pa ml
(range. 1.43-24.8 pa ml-'). A first rise in IL-6 lex els w-as recorded
8 h after oral dosing on day 1. The highest IL-6 concentrations
recorded of 375 pa ml' ± 267.15 pa ml"(median + s.d.) occurred
8 h after administration on dax 5. There were no sianificant
changes in lexels ofIL-1. IL-2 orTNT at any point in the treatment
in any of the patients. Furthermore. the time course of IL-6 induc-
tion closely paralleled that of fever (Figure 1).
DISCUSSION
Fever and flu-like symptoms are troublesome adx erse reactions in
treatment with deoxycytidine analogues. The recent availability of
methods to measure blood lexels of most cytokines allows the
characterization of the pathophysiology in olved in human
diseases. Poplin et al ( 1992 ) first measured the cytokine levels (IL-
2 and TNF) in a phase I trial of gemcitabine because the toxicity
,v as Xerv similar to that obserxed wvith IL-2 therapy. However.
neither cvtokine w as detected at any dose level.
This is the first study in patients receix ing oral FMdC. another
deoxycy'tidine analogue. on a daily x 5-day schedule to show that
eight of ten patients dexeloped a significant rise in plasma levels
of IL-6 after repeated doses. The time course of IL-6 induction
closely paralleled that of fever (Fiaure 1). These results strongly
suggest that IL-6 is at least partly involved in the production of
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Figure 1 Changes in plasma interieukin 6 levels and fever in response to FMdC treatment
fever and flu-like symptoms in treatment with a deoxvcvtidine
analogue.
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